A modified tri-axial electrospinning process was developed for the generation of a 42 new type of pH-sensitive polymer/lipid nanocomposite. The systems produced are 43 able to promote both dissolution and permeation of a model poorly water-soluble drug. 44
Introduction

70
The fabrication of advanced drug delivery systems (DDSs) is increasingly 71 dependent on the creation of complex architectures and understanding 72 structure-activity relationships at the nanoscale [1] [2] [3] . To this end, core-shell 73 nanostructures have been very widely studied in the production of functional 74 Core-shell nanofiber-based DDS have received relatively little attention, and to the 92 best of our knowledge there are no reports of drug-loaded polymer-lipid nanofibers 93 being used in drug delivery. 94
Electrospun nanofibers, comprising an API loaded into a filament-forming 95 polymer, have been the focus of much research. They are prepared from a 96 co-dissolving solution of a drug and polymer; this is ejected from a syringe with 97 electrical energy used to rapidly evaporate the solvent and yield one-dimensional 98 fibers with diameters frequently on the nanoscale. This technique is scalable, and 99 several recent reports address large scale fabrication and the potential for commercial 100 products [19] [20] [21] [22] . The intense research effort invested in these materials thus appears 101 to be about to yield products which can make a major difference to patients' lives. 102
Electrospinning is a facile, one-step procedure, and the products form as a visible and 103 flexible mat which can easily be recovered from the collector without significant loss 104 of material or damage. The nanofibers produced can further be used as templates to 105 manipulate molecular self-assembly to create drug-loaded NPs or liposomes; the 106 electrospinning technique thus provides not only a bridge between fiber-based and 107 NP-based DDSs, but also between solid and liquid dosage forms [23] [24] [25] [26] . 108
The most simple, single-fluid, electrospinning process has been explored for 109 approaching two decades, and the applications of the resultant monolithic nanofibers greatly expanded the range of fibers which can be produced. These include not only 125 core-shell fibers [34, 35] , but also fibers prepared from materials without 126 filament-forming properties [36] and used as templates for creating nanotubes (from 127 the fiber as a whole) or the "bottom-up" generation of NPs (self-assembled from the 128 components loaded in the fibers) [26, 37] . For biomedical applications, core-shell 129 nanofibers proffer a series of new possibilities; for instance, it is possible to protect a 130 fragile active ingredient such as a protein from the stresses of the electrospinning 131 processes by confining it to the core, or to vary the APIs concentration in the core and 132 shell to achieve complex drug release profiles [38] [39] [40] [41] . In the traditional coaxial 133 process the sheath working fluid must be electrospinnable, but a modified process in 134 which one can utilize unspinnable liquids as the sheath fluid is also possible. 
Electrospinning 170
The tri-layer concentric spinneret was homemade. Three syringe pumps 171 (KDS100, Cole-Parmer, Vernon Hills, IL, USA) and a high-voltage power supply 172 (ZGF 60kV/2 mA, Shanghai Sute Corp., Shanghai, China) were used for 173 electrospinning. The collector comprised a flat piece of cardboard wrapped with 174 aluminum foil. All electrospinning processes were carried out under ambient 175 conditions (21 ± 5°C with a relative humidity of 47 ± 5 %). Experiments were 176 recorded using a digital camera (PowerShot A490, Canon, Tokyo, Japan). The 177 spinneret to collector distance was fixed at 15 cm for all experiments. with varied flow rates, as detailed in Table 1 . 185 186 
Characterization 197
Morphology 198
The morphology of the fibers was determined using a Quanta FEG450 field 199 
In vitro dissolution tests 219
To determine drug loading efficiency (LE), 0.100 g of the fibers was added into 220 10 mL of a 10% v/v ethanol solution in water, in order to extract all the loaded DS. 221
The resultant solutions were diluted using phosphate buffered saline (PBS, pH7.0, 222 0.1M) to a suitable concentration for UV measurement. The LE was calculated using 223 the following equation: 224
LE(%) = (DS mass measured)/(theoretical DS mass in the formulation)×100% 225
In vitro dissolution tests were carried out according to the Chinese 226 Pharmacopoeia (2015 Ed.). Method II, which is a paddle method, was undertaken 227 using a RCZ-8A dissolution apparatus (Tianjin University Radio Factory, Tianjin, 228 China). 280 mg of fibers F2 or 20 mg of the DS raw material (particle size <30 μm) 229 were first placed in 600 mL of 0.1 M HCl. Two hours later, 2.4 g NaOH was added to 230 neutralize the dissolution media. The temperature of the dissolution medium was 37 ± 231 1°C and the instrument was stirred at 50 rpm. Sink conditions were maintained, with 232 C < 0.2Cs. At predetermined time points, 5.0 mL aliquots were withdrawn from the 233 dissolution medium and replaced with distilled water to maintain a constant volume. 234
After filtration through a 0.22 µm membrane (Millipore, Billerica, MA, USA) and 235 appropriate dilution with PBS, samples were analyzed at λmax = 276 nm using a 236 UV-vis spectrophotometer (UV-2102PL, Unico Instrument Co. Ltd., Shanghai, 237 China). The cumulative amount of DS released at each time point was back-calculated 238 from the data obtained against a predetermined calibration curve. Experiments were 239 performed seven times, and the average results from six of these replicates are 240
reported as mean ± S.D. 241
During the in vitro dissolution process, dissolution media from the seventh 242 replicate was withdrawn and the transmittance at λ=500 nm measured using the 243 UV-vis spectrophotometer. The average hydrodynamic diameter and size distribution 244 of the particles in the final dissolution medium from these experiments were 245 determined using a BI-200SM static and dynamic light scattering (SDLC) instrument 246 (Brookhaven Instruments Corporation, Austin, TX, USA). 247
Ex vivo permeation tests 248
Ex vivo permeation studies were performed using a RYJ-6A diffusion test 249 apparatus (Shanghai Huanghai Drug Control Instrument Co., Ltd., Shanghai, China), 250 in which materials were mounted in six Keshary-Chien glass diffusion cells and a 251 water bath system maintained a constant temperature of 37 ± 0.2°C. Each cell had a 252 diffusion area of 2.60 cm 2 , and the receptor compartment had a capacity of 7.2 mL 253 PBS (pH7.0, 0.1M). Each donor compartment was filled with 1.0 mL PBS and the 254 hydrodynamics in the receptor compartment were maintained by stirring at 50 rpm 255 with a Teflon coated magnetic bead. Large intestines were obtained from pigs after 256 slaughtering (Baoshan Jiangwan slaughterhouse, Shanghai, China). The intestine was 257 washed carefully with physiological saline solution (NaCl 0.9% w/v) to remove 258 non-digested food. The colonic membranes were peeled away from the intestines and 259 fixed on diffusion cells with the mucosal walls upward. They were equilibrated at 260
35°C for 30 min before permeation tests. 261
The F2 fibers (140 mg) were placed on the mucosal surface in the chambers. 262
Samples (1 mL) were withdrawn from the receptor compartment at timed intervals 263 and 1 mL fresh PBS was added to maintain the volume of fluid here at a constant 264 level. The aliquots were filtered through a 0.22 μm membrane (Millipore, Billerica, 265 MA, USA). The absorption of the filtrate was measured at 276 nm to determine the 266 amount of DS present in the aqueous phase. The semi-solid residue was dissolved 267 using 10 mL of a 10% v/v ethanol solution in water and diluted with PBS before 268 measuring absorbance, in order to determine its DS content of. All measurements 269 were carried out in triplicate. Permeation experiments with 10 mg of pure DS (particle 270 size <30 μm) as a control were also carried out. 271
Statistical analysis 272
The experimental data are presented as mean ± SD. The results from the in vitro 273 dissolution tests and ex vivo permeation tests were analyzed using one-way ANOVA. 274
The threshold significance level was set at 0.05. Thus, p (probability) values lower 275 than 0.05 were considered statistically significant. 276
Results and discussion 277
Implementation of modified tri-axial electrospinning 278
A diagram illustrating the modified tri-axial electrospinning process is shown in 279 The homemade tri-concentric spinneret and its connection with the power supply 300 and three working fluids are shown in Fig. 2a . An alligator clip was used to connect 301 the power supply to the spinneret, which was directly fixed to the syringe holding the 302 outer fluid. The middle and inner fluids were connected to the spinneret through 303 high-elastic silicon tubing. 304
The design of the spinneret is of critical importance in ensuring a robust and 305 reproducible electrospinning process [42, 48] . A well-designed spinneret must provide 306 a suitable template for producing the desired nanofiber architectures, and must be 307 developed bearing in mind the behavior of the working fluids under an electrical field. 308
The spinneret used in this work is exhibited in the top-right and bottom-right insets of 309 periodically to remove semi-solid substances which collected on the spinneret, the 355 resultant ES100 fibers were linear without any beads-on-a-string or 356 spindles-on-a-string morphology ( Fig. 3a1 and 3a2) . These fibers have an average 357 diameter of 1.27 ± 0.13 µm, with an uneven and wrinkled surface ( Table 1, Fig. 3a2) . 358 This is a result of barometric pressure, when residual solvent which was not 359 evaporated during electrospinning escaped from the fibers. Single-fluid 360 electrospinning easily traps solvent in the fibers because of the formation of a solid 361 "skin" on the fluid jet during the solidification process. 362
The F2 fibers are linear with an average diameter of 0.55 ± 0.06 µm and smooth 363 surfaces ( Fig. 3b1 and 3b2, Table 1 ). This can be attributed to the surrounding outer 364 solvent and appropriate selection of the flow rates of the three working fluids (0.5, 2.0 365 and 0.5 mL/h for outer, middle and inner fluids, respectively). If the flow rate of the 366 outer solvent is kept constant and those of the middle and inner fluid altered to 1.6 367 and 0.9 mL/h respectively, the resultant F3 material has many beads clinging to the 368 fibers, although the latter are still linear with an average size of 0.47 ± 0.05 µm (Fig.  369 3b1 and 3b2, Table 1 ). It is thought that this high flow rate of the inner fluid causes it 370 to penetrate the middle and outer fluids to form round PL-DS beads on the fiber 371
surfaces. 372
If the flow rate of the outer solvent is doubled to 1.0 mL/h, the fibers generated 373 exhibit a typical spindles-on-a-string morphology (Fig. 3d1 and 3d2) . Some 374 unexpected clumps are also formed within the fiber mat, as shown in the inset of Fig.  375 3d1. These are ascribed to PL escaping from the inner fluids. A further increase of the 376 outer solvent flow rate was found to result in an electrospraying process. These results 377 demonstrate that the selection of flow rates is a key parameter which must be 378 controlled to ensure the formation of a core-shell nanostructure. confirming the presence of PL with ES100. However, the characteristic peaks from 426 the benzene rings of DS cannot be seen in the F2 spectrum. This can be attributed to 427 secondary interactions between PL and DS. Hydrophobic interactions, in addition to 428 possible hydrogen bonding and electrostatic interactions, can arise between all three 429 components in F2, as is clear from a consideration of the molecular structures in Fig.  430 6. These secondary interactions should ensure that the drug and excipients are highly 431 compatible, favorable for the stability of the core-shell nanocomposites. 
Functional performance 441
DS has a maximum absorbance at 276 nm, which was used to construct a 442 calibration curve: A=0.0085+0.0279 C (R=0.9997) within a linear range from 2 to 50 443 µg/mL. The drug content in F2 was first assayed, and found to be 7.26 ± 0.31% (n = 444 6), almost identical to the calculated value of 7.14%. 445
The in vitro release profiles of F2 and the DS starting material are shown in Fig.  446 7a. DS is virtually insoluble in acidic conditions, with a small increase in solubility 447 when the pH is raised to neutral. After 2 h in acid, 2.8% of DS from the raw material 448 was freed into the dissolution media. When the pH was raised to neutral, the DS 449 particles gradually dissolved over ca. 3 hours. For F2, 2.1% of the loaded DS was 450 released during the first 2 h. In the neutral dissolution media, the nanofibers released a 451 total of 79.1% of the incorporated DS over 22 h. 452 ES100 is a pH-sensitive polymer, and is insoluble at pHs below 7.0; it can thus 453 be used to target DS to the colon region. DS is a popular API for oral administration 454
and is frequently used in the treatment of pain and peri-operatively. However, it can 455 easily result in an anaphylactic reaction, and to an allergic reaction in the digestive 456 tract [52, 53] . With traditional electrospun nanofibers, the drug is released by diffusion 457 through an insoluble polymeric matrix, or by an erosion mechanism from a 458 water-soluble carrier (or a combination of both processes) [39, 43] . Here the drug 459 release from the core-shell composites is expected to include two successive steps 460 (Fig. 7b) . First, dissolution of the pH-sensitive ES100 shell will occur, with some 461 diffusion of DS from the insoluble core PL. After dissolution of the shell ES100, the 462 core PL-DS is not thought to be able to endure the shear forces of stirring applied 463 during the experiment and thus we propose that the core is broken up into PL-DS 464 particles. The DS is then gradually released from the resultant DS-PL aggregates. 
478
To further investigate the drug release mechanism and validate this hypothesis, 479 the transmittance of the dissolution media and light scattering studies were performed. 480
The changes in transmittance at λ=500 nm are shown in Fig. 8a . DS has no 481 absorbance above 320 nm, and thus any turbidity of the dissolution media recorded at 482 this wavelength must result from the formation of a PL-DS suspension. In the first 2 h, 483 the transmittance remains virtually constant. After the pH is raised to neutral, the 484 transmittance values decreased for 3 h, after which they level out at around 77%. This 485 is consistent with the dissolution of the shell ES100 occurring over this period and 486 resulting in PL-DS nanoparticles. 487
The SDLC results obtained on the final dissolution medium are given in Fig. 8b . 488 The results of permeation tests are presented in Fig. 9 . DS is a Biopharmaceutical 497 class II drug, meaning it is poorly water-soluble but is able to effectively cross fatty 498 membranes [54] . After 12 h only 3.7 mg of the pure drug was transmitted into the 499 receptor cells. The dissolution of DS is very slow because there is only a very limited 500 amount of aqueous medium in the donor cell (cf. the dissolution experiments, which 501 are performed under sink conditions) [55] . For the F2 fibers, both dissolved DS and 502 the PL-DS particles penetrate the bio-membranes into the receptor cells [56] . 503
Although the core-shell nanofibers provided sustained release of DS in dissolution 504 studies (much slower than the release from pure DS), after 12 h 8.1 ± 0.46 mg DS 505 from F2 had entered the receptor chamber. Of this amount, 1.7 ± 0.23 mg was present 506 in the aqueous phase (or in particles below 220 nm in size, which could pass through 507 the filters used). This suggests that (8.1-1.7)/8.1×100=79% of the DS penetrated 508 through the mucosal membrane in the format of PL-DS particles. For oral 509 administration applications, this drug delivery route should alleviate any potential 510 allergic reactions with the digestive tracts. 511
Many commercial tablets are essentially a physical mixture of drug powders and 512 polymeric carrier, the latter being added to modulate the drug release behavior. The 513 combined use of polymer and lipid in the fibers prepared in the work is able to both 514 protect the API from release in the stomach and provide sustained release in the 515 colonic region, and also ensure improved trans-membrane permeability, leading to 516 more effective absorbance. This strategy is particularly useful for oral delivery of 517
Class IV drugs (which are both poorly water-soluble and have poor permeation 518 properties). Drug-loaded electrospun fibers can easily be converted into routine oral 519 solid dosage forms such as tablets and capsules using traditional pharmaceutical 520 protocols [57] [58] [59] . 521 522 Fig. 9 . Ex vivo permeation profiles of the F2 fibers and pure DS (n=6). 523 524
Perspectives 525
Coaxial electrospinning is often regarded as a major breakthrough in this field 526
[60,61]. The fact that only one of the working fluids needs to be electrospinnable for a 527 successful coaxial process significantly widens the range of materials which can be 528 processed, and a very broad family of core-shell nanostructures can be produced. 529
There are only about 100 polymers which can be directly electrospun into fibers, and 530 often these can only be processed within a narrow window of conditions 531 (concentration, voltage, etc). The introduction of unspinnable fluids in the modified 532 coaxial processes greatly expands the capability of this simple technology to produce 533 nanoscale products from a large range of raw materials. Furthermore, modified 534 coaxial electrospinning permits all types of liquid phase (including solvents, small 535 molecule solutions, dilute polymer solutions, suspensions and also emulsions) to be 536
processed. 537
In this work, we report the first example of modified tri-axial electrospinning. 538
Similar to modified co-axial spinning, this moves technology beyond the traditional 539 tri-axial process in which all three working fluids are required to be individually 540 electrospinnable. In our work, two of the three fluids were unspinnable alone: an 541 electrospinnable middle layer fluid is sufficient to ensure a successful tri-axial process. 542
This proof-of-concept work indicates that there are many possibilities in developing 543 functional nanofibers through the introduction of unspinnable outer-layer and 544 inner-layer working fluids into tri-axial processes. 545
The feasibility of the different tri-axial electrospinning processes which can be 546 
Conclusions 569
A modified tri-axial electrospinning process was successfully implemented to create 570 core-shell nanofibers, in which a spinnable Eudragit S100 (ES100) solution was used 571 as the middle fluid to support the outer solvent and an unspinnable phosphatidyl 572 choline (PL)/diclofenac sodium (DS) inner solution. This resulted in a continuous and 573 trouble-free nanofabrication process. The resultant core-shell nanofibers have a linear 574 morphology with an obvious core-shell structure. XRD demonstrated that the 575 nanofibers are structural nanocomposites with both the drug DS and also the lipid 576 carrier PL losing their original crystalline physical forms and being transferred into an 577 amorphous state. These core (PL-DS)-shell (ES100) nanostructures can protect the 578 drug from release in acidic conditions to give colon-targeted release. They release the 579 drug through two successive steps at neutral pH: first, dissolution of the shell ES100 580 occurs, which is believed to generate PL-DS sub-micron sized particles. Subsequently, 581 release of DS from the particles occurs. The composite nanofibers lead to more than 582 twice as much drug permeation through the colonic bio-membrane when compared 583 with pure DS. The tri-axial electrospinning process developed in this work should 584 provide a new platform to fabricate structural nanomaterials, and polymer-PL 585 nanocomposites such as those prepared here can be utilized for effective oral drug 586
delivery. 587
Acknowledgements 588
This work was supported by the China NSFC/UK Royal Society cost share 589 international exchanges scheme (No. 51411130128/IE131748), the National Science 590 Table 1 . Key details of the electrospinning processes and resultant fibers 772 in solution and in very small particles (< 220 nm) which could pass through the 794 filtration membrane used. Thus, some portion of the DS which had permeated in the 795 "free in water" experiment could in fact be in very small nanoparticles. 796 
